People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Space / Aerospace, Biotechnology, Investment Vehicle, Other Health Care, Cybersecurity, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Space Exploration Technologies Corp | — | Space / Aerospace | Growth/Late | $9.0B | $4.4B | 2009 |
| G.I. Windows, Inc. | — | Biotechnology | Series B | $76.9M | $218.1M | 2022 |
| COTA Emerald City Fund LP | — | Investment Vehicle | Series C | $46.5M | $426.0M | 2023 |
| Bariendo Inc. | — | Biotechnology | Series A | $11.1M | $40.9M | 2025 |
| BEACON ENDOSCOPIC Corp | — | Other Health Care | Seed | $6.1M | $29.8M | 2011 |
| Cyber Physical Systems, Inc. | — | Cybersecurity | Seed | $5.7M | $63.0M | 2012 |
| Empathy Health Technologies Inc. | — | Healthtech | Series A | $4.2M | $21.3M | 2024 |
| TriplePulse, Inc. | — | Retailing | Pre-Seed | $2.3M | $3.3M | 2015 |
Christopher Thompson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Thompson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Tinkham | 2 | 3 |
| Antonio Gracias | 1 | 15 |
| Steve Jurvetson | 1 | 10 |
| James Wright | 1 | 9 |
| Stephen Reeders | 1 | 9 |
| FRED MOLL | 1 | 8 |
| Frederic H. Moll | 1 | 8 |
| Byron Smith | 1 | 8 |
| Robert Epstein | 1 | 8 |
| David Neustaedter | 1 | 7 |
| Elon Musk | 1 | 6 |
| David Harris | 1 | 6 |
| V. Kadir Kadhiresan | 1 | 5 |
| Kimbal Musk | 1 | 5 |
| Eric Satz | 1 | 5 |
| Steve R Jurvetson | 1 | 3 |
| Kurt Rechner | 1 | 3 |
| Harry Zimmerman | 1 | 3 |
| Thomas Mueller | 1 | 2 |
| Hans Koenigsmann | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.